Page last updated: 2024-12-06
theodrenaline
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 71857 |
| CHEMBL ID | 2107608 |
| CHEBI ID | 135580 |
| SCHEMBL ID | 150110 |
| MeSH ID | M0043466 |
Synonyms (38)
| Synonym |
|---|
| 7-(2-{[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino}ethyl)-1,3-dimethyl-3,7-dihydro-1h-purine-2,6-dione |
| theodrenaline (inn) |
| 13460-98-5 |
| D07155 |
| theodrenalinum [inn-latin] |
| d 470 |
| 7-(2-((2-(3,4-dihydroxyphenyl)-2-hydroxyethyl)amino)ethyl)theophylline |
| 7-(2-(2-hydroxy-2-(3,4-dihydroxyphenyl)ethylamino)ethyl)theophylline |
| 7-(2-(2-(3,4-dihydroxyphenyl)-2-hydroxyethylamino)ethyl)theophylline |
| teodrenalina [inn-spanish] |
| theodrenaline [inn:ban] |
| theodrenalina [dcit] |
| theodrenaline |
| theophylline, 7-(2-((2-(3,4-dihydroxyphenyl)-2-hydroxyethyl)amino)ethyl)- |
| noradrenaline theophylline |
| brn 0590101 |
| norphedrinoethyltheophylline |
| CHEBI:135580 |
| 7-[2-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]ethyl]-1,3-dimethylpurine-2,6-dione |
| CHEMBL2107608 |
| theophylline, 7-(2-((beta,3,4-trihydroxyphenethyl)amino)ethyl)- |
| teodrenalina |
| theodrenalinum |
| unii-rw8pd99t8g |
| rw8pd99t8g , |
| 5-26-14-00012 (beilstein handbook reference) |
| theodrenalina |
| AKOS015913854 |
| theodrenaline [inn] |
| (+/-)-7-(2-(2-(3,4-dihydroxyphenyl)-2-hydroxyethylamino)ethyl)theophylline |
| theodrenaline [who-dd] |
| SCHEMBL150110 |
| theodrenalin |
| HY-U00344 |
| CS-7379 |
| DB12927 |
| Q7782198 |
| DTXSID40864406 |
Drug Classes (1)
| Class | Description |
|---|
| oxopurine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 34.77
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 34.77 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.62 (4.65) | | Search Engine Demand Index | 31.50 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (16.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Effect of Cafedrine/Theodrenaline and Urapidil During Carotid Endarterectomy on Cerebral Oxygenation Measured by Near Infrared Spectroscopy [NCT01311414] | | 0 participants (Actual) | Interventional | | Withdrawn(stopped due to The study was suspended due to organizational problems) |
| Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting: a Multicenter, Prospective, Non-interventional Study [NCT02893241] | | 2,013 participants (Actual) | Observational | 2016-04-30 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |